Y-Mabs Therapeutics Inc (YMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 87,685 | 84,819 | 65,267 | 34,897 | 20,750 |
| Cost of Goods | 15,001 | 11,366 | 7,467 | 2,304 | N/A |
| Gross Profit | 72,684 | 73,453 | 57,800 | 32,593 | 20,750 |
| Operating Expenses | 103,886 | 99,491 | 153,078 | 148,330 | 140,685 |
| Operating Income | -31,201 | -25,672 | -94,811 | -115,433 | -119,935 |
| Other Income | 1,389 | 4,806 | -757 | 60,158 | 598 |
| Pre-tax Income | -29,812 | -20,866 | -95,568 | -55,275 | -119,337 |
| Income Tax | -146 | 561 | N/A | N/A | N/A |
| Net Income Continuous | -29,666 | -21,427 | -95,568 | -55,275 | -119,337 |
| Net Income | $-29,666 | $-21,427 | $-95,568 | $-55,275 | $-119,337 |
| EPS Basic Total Ops | -0.67 | -0.49 | -2.19 | -1.28 | -2.97 |
| EPS Basic Continuous Ops | -0.67 | -0.49 | -2.19 | -1.28 | -2.97 |
| EPS Diluted Total Ops | -0.67 | -0.49 | -2.19 | -1.28 | -2.97 |
| EPS Diluted Continuous Ops | -0.67 | -0.49 | -2.19 | -1.28 | -2.97 |
| EPS Diluted Before Non-Recurring Items | -0.67 | -0.49 | -2.19 | -1.28 | -2.97 |
| EBITDA(a) | $-30,666 | $-24,937 | $-93,972 | $-114,651 | $-119,539 |